ROCKET PHARMACEUTICALS, INC. (RCKT)
2025-06-30 | 2025-03-31 | 2024-09-30 | ||
|---|---|---|---|---|
| Revenue | - | - | - | |
| Restructuring | 3,471 | - | - | |
| Research and development | 42,658 | 35,942 | 42,315 | |
| General and administrative | 25,020 | 28,446 | 27,109 | |
| Total operating expenses | 71,149 | 64,388 | 69,424 | |
| Loss from operations | -71,149 | -64,388 | -69,424 | |
| Interest expense | 473 | 472 | 471 | |
| Interest and other income, net | 483 | 1,336 | 1,327 | |
| Accretion of discount on investments, net | 2,220 | 2,190 | 1,849 | |
| Net loss | -68,919 | -61,334 | -66,719 | |
| Earnings per share, basic, total | -0.62 | -0.56 | -0.71 | |
| Earnings per share, diluted, total | -0.62 | -0.56 | -0.71 | |
| Weighted average number of shares outstanding, basic, total | 111,019,647 | 110,093,461 | 94,158,491 | |
| Weighted average number of shares outstanding, diluted, total | 111,019,647 | 110,093,461 | 94,158,491 | |